| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Additional Infomation |
Sulfamethopyrazine belongs to the pyrazine class of compounds and is a sulfonamide antibiotic. It is a long-acting plasma-bound sulfonamide used to treat respiratory tract infections, urinary tract infections, and malaria. Sulfamethopyrazine is a long-acting sulfonamide antibiotic used to treat chronic bronchitis, urinary tract infections, and malaria. It is a long-acting plasma-bound sulfonamide used to treat respiratory tract infections, urinary tract infections, and malaria. Indications: Used to treat urinary tract infections and chronic bronchitis. Mechanism of Action: Sulfamethopyrazine is a competitive inhibitor of bacterial dihydropteranoic acid synthase. It prevents the binding of this enzyme's substrate, para-aminobenzoic acid (PABA). In these organisms, this inhibited reaction is essential for folic acid synthesis. Pharmacodynamics: Sulfamethopyrazine is a sulfonamide antibiotic. Sulfonamides are synthetic antibacterial antibiotics with broad-spectrum antibacterial activity against most Gram-positive bacteria and many Gram-negative bacteria. However, many strains of the same species may develop resistance. Sulfonamides inhibit bacterial growth by competitively inhibiting para-aminobenzoic acid in the folate metabolic cycle. Bacteria have similar sensitivity to various sulfonamides; resistance to one sulfonamide means resistance to all sulfonamides. Most sulfonamides are well absorbed orally. However, parenteral administration is difficult because soluble sulfonamide salts are strongly alkaline and irritating to tissues. Sulfonamides are widely distributed in all tissues. High concentrations are found in pleural effusions, ascites, synovial fluid, and intraocular fluid. Although these drugs are no longer used to treat meningitis, high concentrations remain in cerebrospinal fluid during meningeal infections. Pus can inhibit their antibacterial activity.
|
|---|
| Molecular Formula |
C11H12N4O3S
|
|---|---|
| Molecular Weight |
280.3
|
| Exact Mass |
280.063
|
| CAS # |
152-47-6
|
| Related CAS # |
Sulfalene-13C6
|
| PubChem CID |
9047
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
488.6±55.0 °C at 760 mmHg
|
| Melting Point |
270 °C (dec.)(lit.)
|
| Flash Point |
249.3±31.5 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.647
|
| LogP |
1.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
376
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])(N([H])C1C(=NC([H])=C([H])N=1)OC([H])([H])[H])(=O)=O
|
| InChi Key |
KXRZBTAEDBELFD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H12N4O3S/c1-18-11-10(13-6-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)
|
| Chemical Name |
4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide
|
| Synonyms |
Sulfaleno; Sulfalene; Sulfalen
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~356.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5676 mL | 17.8380 mL | 35.6761 mL | |
| 5 mM | 0.7135 mL | 3.5676 mL | 7.1352 mL | |
| 10 mM | 0.3568 mL | 1.7838 mL | 3.5676 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.